Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetics-Guided Maintenance After Allo-HSCT for AML/MDS
NCT06972641Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2025
- Primary completion
- Mar 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label trial of decitabine, sorafenib, gilteritinib, avapritinib, venetoclax and 1 more in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (4 arms), sponsored by Ruijin Hospital. Primary endpoint: Event-Free Survival at 2 years. Started Jun 2025; status: recruiting.
02
Drugs
decitabinesorafenibgilteritinibavapritinibvenetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT06972641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972641.